A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer

Thromboembolism (TE) is a well-recognized complication among patients with non-small cell lung cancer (NSCLC), occurring throughout the disease course with an incidence commonly reported between 10-15% and exceeding 20% in some populations. [1,2] TE in cancer patients is associated with worse prognosis [3].

Source: Lung Cancer - January 21, 2020 Category: Cancer & Oncology Authors: Marliese Alexander, B. Pharm, Nick Pavlakis, Thomas John, Rachel O'Connell, Steven Kao, Brett Hughes, Adrian Lee, Sarah A Hayes, Viive M Howell, Stephen J Clarke, Michael Millward, Kate Burbury, Benjamin Solomon, Malinda Itchins Source Type: research